Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Leadership Transition - Carl Hull, founder of Maravai, will retire as Executive Chairman of the Board, effective December 5, 2024 [1] - R Andrew Eckert has been unanimously elected by the Board of Directors to succeed Carl Hull as Chairman of the Board [1] - Carl Hull founded Maravai in 2014 and served as CEO before assuming the role of Executive Chairman in October 2022 [2] Carl Hull's Legacy - Carl Hull expressed pride in Maravai's accomplishments over the past 10 years and confidence in the company's future prospects [3] - Constantine Mihas, Board member and Co-CEO of GTCR, praised Carl Hull's vision and leadership in building Maravai and positioning it for long-term success [3] R Andrew Eckert's Background - R Andrew Eckert is a healthcare industry veteran with extensive executive experience, including CEO roles at Zelis, Kinetic Concepts Inc, Valence Health, TriZetto, CRC Health Group, Eclipsys Corporation, and SumTotal Systems [4] - Eckert has served on several corporate boards, including Chairman of Kipu Health, Lead Director at Fortrea, and Director at Becton, Dickinson and Company [4] - Eckert holds a Bachelor of Science in Industrial Engineering and a Master of Business Administration from Stanford University [4] Maravai's Industry Position - Maravai is a leading life sciences company providing critical products for drug therapies, diagnostics, novel vaccines, and research on human diseases [5] - The company is a leader in nucleic acid synthesis and biologics safety testing, serving many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies [5]